by Brandon Burley and The Redemption Project
Federal detections of a new synthetic opioid show why drug markets do not spread state by state the way most people assume.
Federal laboratory detections of a new synthetic opioid known as N-propionitrile chlorphine are raising broader questions about how emerging drug compounds move through U.S. supply networks.
The compound was first confirmed by a DEA laboratory in 2024, with later detections reported in states including Texas, California, Illinois, Missouri, and Tennessee.
New Mexico reports no confirmed identifications to date.
State officials say the compound has not been detected in seized materials there, but that existing laboratory workflows would be capable of identifying it if it appeared.
Forensic experts note that synthetic opioids do not spread state by state in a predictable pattern.
They move through trafficking networks, wholesale relationships, and supply hubs, often appearing in one region while remaining absent in nearby states.
That means the more important question is not whether a compound has reached a state yet.
It is whether surveillance systems are prepared to recognize it when it does.
Drug markets often follow relationships, logistics, and supply chains rather than geography.
A compound may surface repeatedly in one region while remaining absent nearby for months or longer.
That is why laboratory readiness often matters more than assumptions based on maps.
I am a retired detective and criminal justice / government educator based in Tennessee. I am a commentary write for Tennessee Lookout and a weekly columnist with Knox TN Today. My work examines public policy, public safety systems and civic responsibility. My reporting and commentary have also appeared in Governing, The Arizona Capitol Times, South Florida Sun Sentinel, Police1, among other state and regional outlets.
